Insights: News Releases Kilpatrick Townsend’s Andrew Serafini Appointed to the Board of Directors of Washington Biotechnology & Biomedical Association
SEATTLE (February 2) – Kilpatrick Townsend & Stockton announced today that partner Andrew T. Serafini, Ph.D. has been appointed to Washington Biotechnology & Biomedical Association’s (WBBA) Board of Directors.
The WBBA is a trade association serving the life sciences industry in the state of Washington and has 650 member organizations. The WBBA's mission is to "support and help to grow Washington state's life science ecosystem." To learn more about the WBBA, please visit http://www.washbio.org/.
Dr. Serafini is a registered patent attorney who focuses his practice on strategic and comprehensive intellectual property counseling and management to biotechnology, biopharmaceutical and other life sciences clients. He assists his clients in obtaining, protecting and enforcing their intellectual property rights, especially in the areas of immunology, molecular biology, antibody engineering and therapeutics, vaccines, stem cell technologies, molecular genetics, genomics, proteomics and protein chemistry, pharmaceuticals, medical therapeutics, nanotechnology, clean energy, medical diagnostics and personalized medicine.
Follow the firm on Twitter: @KTS_Law.
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.